Search Result

Isoforms Recommended:	ErbB2/HER2

Results for "

HER-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (219) ADC Antibody (7) ADC Linker (1) ADC Payload (8) Akt (24) Antibody-Drug Conjugates (ADCs) (17) Apoptosis (43) Arenavirus (1) Autophagy (14) Bcl-2 Family (2) Biochemical Assay Reagents (2) Btk (3) c-Met/HGFR (9) Caspase (5) CD3 (2) Cdc42-binding kinase (1) CDK (33) COX (2) Dengue Virus (1) Dihydrofolate reductase (DHFR) (3) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (2) Drug-Linker Conjugates for ADC (12) Endogenous Metabolite (1) Epigenetic Reader Domain (3) ERK (8) Estrogen Receptor/ERR (7) Eukaryotic Initiation Factor (eIF) (1) Fatty Acid Synthase (FASN) (1) Fc Receptor (FcR) (1) Fluorescent Dye (2) HDAC (2) Heme Oxygenase (HO) (1) Histone Acetyltransferase (3) HSP (16) IFNAR (1) IGF-1R (1) Interleukin Related (2) Isotope-Labeled Compounds (8) Itk (1) JAK (1) JNK (1) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (1) LYTACs (1) MHC (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) MMP (4) Monoamine Oxidase (2) mTOR (2) Necroptosis (1) NF-κB (1) NO Synthase (1) p38 MAPK (10) PAK (1) PARP (5) PD-1/PD-L1 (2) PDGFR (3) Photosensitizer (1) PI3K (9) PI4K (1) Potassium Channel (1) PROTAC-Linker Conjugates for PAC (2) PROTACs (4) Proteasome (1) Radionuclide-Drug Conjugates (RDCs) (5) Raf (1) Ras (3) Reactive Oxygen Species (ROS) (2) Reference Standards (21) SARS-CoV (1) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (2) Src (3) Steroid Sulfatase (1) STING (1) Survivin (2) Thymidylate Synthase (2) TNF Receptor (4) Toll-like Receptor (TLR) (7) Topoisomerase (8) Transmembrane Glycoprotein (2) Trk Receptor (1) TSPO (1) VEGFR (13) VSV (1) Wnt (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (324) Cardiovascular Disease (2) Infection (6) Inflammation/Immunology (16) Metabolic Disease (2) Neurological Disease (8)
Click Chemistry:	ADC Synthesis (1) TCO (1) PROTAC Synthesis (1) Azide (3) Alkynes (2)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) Antisense Oligonucleotides (1) siRNAs (2)

332

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Trastuzumab Maximum Cited Publications 55 Publications Verification Anti-Human HER2, Humanized Antibody	Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody	Cancer
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to *HER2* with high affinity. Trastuzumab can be used for the research of *HER2*-positive metastatic breast cancer and gastric cancer ^[2] . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

*Trastuzumab (anti-HER2)* Maximum Cited Publications 55 Publications Verification Anti-Human HER2, Humanized Antibody (anti-HER2)	ADC Antibody EGFR	Cancer
Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

Pertuzumab 5+ Cited Publications	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

Trastuzumab vedotin 2 Publications Verification MRG002; Trastuzumab MMAE	Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin	Cancer
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting *HER2, with a K_d of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing* cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma ^[2].

Sevabertinib BAY 2927088	EGFR	Cancer
Sevabertinib (BAY 2927088) is an orally active and reversible dual *EGFR-HER2* inhibitor (IC ⁵⁰ <0.5 nM for wild-type HER2, HER2 A775insYVMA, wild-type EGFR, and EGFR D770_N771insSVD). Sevabertinib has anticancer activity against lung cancer ^[2].

Mubritinib 5+ Cited Publications TAK-165	EGFR	Cancer
Mubritinib (TAK-165) is a potent and selective *EGFR2/HER2* inhibitor with an IC₅₀ of 6 nM.

Tuxobertinib 1 Publications Verification BDTX-189	EGFR	Cancer
Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and *HER2* oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows K_Ds of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity .

*Pertuzumab (anti-HER2)*	EGFR	Cancer
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

Nesfrotamig YH32367; ABL105	TNF Receptor	Cancer
Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting *HER2* and 4-1BB. The K_d values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors ^[2] .

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Cancer
Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a K_a of 3.55e-10 M for human *Her2* and a K_a of 1.17e-9 M for human PD-1. Fidasimtamab cross-links *Her2*-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on *Her2*-positive gastric cancer .

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human *HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2* signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer ^[2] .

Trastuzumab rezetecan SHR-A1811	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab rezetecan (SHR-A1811) is a *HER2*-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

Cinrebafusp alfa PRS 343	EGFR TNF Receptor	Cancer
Cinrebafusp alfa (PRS 343) is a high affinity *CD137/HER2* bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (K_d=0.3 nM) and human monomeric CD137 (4-1BB; K_d=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research ^[2].

Margetuximab MGAH-22	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

*PROTAC HER2* degrader-1**	PROTACs EGFR Apoptosis Akt ERK	Cancer
PROTAC HER2 degrader-1 is a highly selective *HER2* PROTAC degrader, with a DC₅₀ of 69 nM and a D_max of 96%. PROTAC HER2 degrader-1 inhibits HER2-positive cell proliferation and tumor growth through persistent *HER2* degradation and potent inhibition of downstream pathways (AKT and ERK). PROTAC HER2 degrader-1 induces apoptosis in BT-474 cells. PROTAC HER2 degrader-1 can be used for research of HER2-positive cancers. (Pink: HER2 ligand: (HY-177009); Black: Linker; Blue: CRBN ligand: (HY-W023573) .

IRDye700Dx (Maleimide)	Fluorescent Dye Photosensitizer	Cancer
IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in *HER2*-positive breast cancer cells without causing damage to *HER2*-negative breast cancer cells .

ErbB-2-binding peptide HER2-binding peptide	EGFR	Cancer
ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. ErbB-2-binding peptide has the potential for cancer research .

*Anti-Human/Rat HER2* (neu) Antibody (7.16.4)**	EGFR	Inflammation/Immunology Cancer
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is an anti-human and anti-rat *HER2* IgG2a monoclonal antibody. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) reduces tumor cell proliferation by inhibiting the HER2 signaling pathway. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can activate CD8 ⁺ T cells. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can be used for research on cancer such as breast cancer ^[2].

Gancotamab antibody MM-302 antibody	EGFR	Cancer
Gancotamab antibody (MM-302) is a *HER2*-targeted antibody with antitumor activity .

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a *HER2* targeting peptide that binds to *HER2* to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

SHR-A1201	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
SHR-A1201 is a *HER2*-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .

SPH5030	EGFR	Cancer
SPH5030 is a selective and irreversible *HER2* inhibitor. SPH5030 inhibits HER2 ^WT and EGFR ^WT with IC₅₀s of 3.51 and 8.13 nM, respectively. SPH5030 shows excellent activities against HER2 mutants. SPH5030 can be used for the research of cancer .

AG 1406	EGFR	Cancer
AG 1406 (compound M19) is a *HER2* inhibitor, with an IC₅₀ of 10.57 μM for HER2 in BT474 cell and >50 μM for EGFR in EGF-3T3 cell .

*Biotin HER-2* substrate peptide**	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

MC-Val-Cit-PAB-Amide-TLR7 agonist 4	EGFR Toll-like Receptor (TLR)	Inflammation/Immunology
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a *HER2-TLR7* and *HER2-TLR8* immune agonist conjugate .

Nelipepimut-S	EGFR	Cancer
Nelipepimut-S is a peptide vaccine which targets *HER2. Nelipepimut-S has immune activity against HER2* positive breast cancer .

*Anti-Mouse/Human/Canine HER2* (domain III) Antibody (H2Mab-19)**	EGFR	Cancer
Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) reacts with domain III of human and canine HER2. Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) exerts antitumor activity in mouse oral cancer xenografts. Recommend Isotype Controls: Mouse IgG2b kappa, Isotype Control (HY-P99982) .

HER2-IN-23	EGFR PARP	Cancer
HER2-IN-23 is a selective *HER2* inhibitor. HER2-IN-23 reduces in total HER2 expression rather than in phosphorylated HER2 (p-HER2). HER2-IN-23 reduces cyclin D1 level and stimulates PARP cleavage. HER2-IN-23 can be used for the study of HER2-positive breast cancer .

HER2-IN-22	EGFR Apoptosis	Cancer
HER2-IN-22 is a potent and selective *HER2* inhibitor with an IC₅₀ of 215 μM. HER2-IN-22 possesses killing activity against various tumor cells and can induce cell apoptosis. HER2-IN-22 significantly inhibits tumor growth. HER2-IN-22 can be used in the study for tumors such as HER2+ breast cancer .

HER2-IN-12	EGFR	Cancer
HER2-IN-12 is a *HER2* inhibitor (IC₅₀: 121 nM). HER2-IN-12 can be used in the research of cancers, such as breast cancer .

HER2-IN-17	EGFR	Cancer
HER2-IN-17 (Compound 2) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-17 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HER2-IN-5	EGFR	Cancer
HER2-IN-5 is a potent and orally active *HER-2* inhibitor, example 10, extracted from patent WO2021164697 .

*EGFR/HER2-IN-18*	EGFR	Cancer
EGFR/HER2-IN-18 is a stable *EGFR/HER2* dual inhibitor with IC₅₀ values of 0.09 (EGFR) and 0.08 μM (HER2) respectively. EGFR/HER2-IN-18 exhibits broad-spectrum anti-cancer activity. EGFR/HER2-IN-18 induces MCF-7 cells apoptosis and inhibits the cell cycle. EGFR/HER2-IN-18 can be used for the study of breast cancer .

MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic	EGFR Toll-like Receptor (TLR)	Inflammation/Immunology
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic (example 15) is a *HER2-TLR7* and *HER2-TLR8* immune agonist conjugate .

COVA208	EGFR p38 MAPK PI3K Akt	Cancer
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets *HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive* breast cancer, gastric cancer, and colorectal cancer .

Cyclic(YCDGFYACYMDV)	EGFR Apoptosis	Cancer
Cyclic(YCDGFYACYMDV) is a *HER2* signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to *HER2* on cancer cells. This transformation disrupts *HER2* dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on *HER2* positive breast cancer have been demonstrated to be effective in a murine xenograft model .

SG3376	EGFR Drug-Linker Conjugates for ADC	Cancer
SG3376 is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). SG3376 is promising for research of HER2-overexpressing cancers (e.g., breast, gastric cancer) .

LE01	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
LE01 is a drug-linker conjugate for ADC. LE01 contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D). LE01 can be used to synthesize HER2-targeting ADC (HER2-LE01) .

Trastuzumab envedotin DP303c	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .

TAS2940	EGFR	Cancer
TAS2940 is a brain-penetrable, orally active, irreversible and selective pan-ERBB inhibitor. TAS2940 against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC₅₀ values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 can be used for the study of tumors with HER2 and EGFR aberrations .

*EGFR/HER2-IN-16*	Apoptosis EGFR	Cancer
EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of EGFR (IC₅₀=6.15 nM) and *HER-2* (IC₅₀=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research .

HER2-IN-9	EGFR	Cancer
HER2-IN-9 is an orally active *HER2* inhibitor, with an IC₅₀ value of 0.03 μM. HER2-IN-9 inhibits HER-2 positive breast cancer cells proliferation and migration. HER2-IN-9 can be used in the research of breast cancers .

HER2-IN-10	Apoptosis	Cancer
HER2-IN-10 is a psoralen derivative. HER2-IN-10 has anti-breast cancer activity and light-activated cytotoxicity. HER2-IN-10 induces apoptosis .

HER2-IN-11	Apoptosis	Cancer
HER2-IN-11 is a psoralen derivative. HER2-IN-11 has anti-breast cancer activity and light-activated cytotoxicity. HER2-IN-11 induces apoptosis .

HER2-IN-8	EGFR	Inflammation/Immunology Cancer
HER2-IN-8 is a *HER-2* inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation .

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library

4,096 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 4,096 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

HY-L177

Antibody Inhibitor Library

1,777 compounds

Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.

MCE can provide 1,777 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

HY-L184

Anti-Gastric Cancer Compound Library

1,122 compounds

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 1,122 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

HY-L074

Anti-Breast Cancer Compound Library

3,181 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 3,181 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-138298

Trastuzumab deruxtecan (solution)

5 Publications Verification

T-DXd (solution); DS-8201 (solution); DS-8201a (solution)

Fluorescent Dyes

Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer ^[2].

HY-138298A

Trastuzumab deruxtecan

5 Publications Verification

T-DXd; DS-8201; DS-8201a

Fluorescent Dyes

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer ^[2].

HY-P9921A

Trastuzumab emtansine (solution)

Maximum Cited Publications

6 Publications Verification

Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)

Fluorescent Dyes

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer ^[2].

HY-164992

Trastuzumab vedotin

2 Publications Verification

MRG002; Trastuzumab MMAE

Fluorescent Dyes

Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a K_d of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma ^[2].

HY-164919

Calotatug ginistinag XMT-2056	Fluorescent Dyes
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting *HER2, with an effective payload connected via a linker (LP, HY-148067) to a STING* agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity .

HY-164762

Trastuzumab rezetecan SHR-A1811	Fluorescent Dyes
Trastuzumab rezetecan (SHR-A1811) is a *HER2*-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-D2309

IRDye700Dx (Maleimide)	Fluorescent Dyes
IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in *HER2*-positive breast cancer cells without causing damage to *HER2*-negative breast cancer cells .

HY-P9994

Pertuzumab zuvotolimod

SBT6050

Fluorescent Dyes

Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .

HY-172820

Trastuzumab envedotin

DP303c

Fluorescent Dyes

Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .

HY-177414

BB-1701

Fluorescent Dyes

BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 is composed of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), a microtubule inhibitor (Eribulin) (HY-13442), and the drug-linker conjugate for ADC is Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 has a potent cytotoxicity and bystander effects on tumors with heterogeneous target expression. BB-1701 significantly induces immunogenic cell death and the activation of the immune .

Cat. No.	Product Name	Type

HY-W016412

Coenzyme Q0

2 Publications Verification

CoQ0

Biochemical Assay Reagents

Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling ^[2] .

HY-W088413A

DOTA-amide dihydrate	Biochemical Assay Reagents
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to *HER2* and can be used to detect bone metastases, which are common in prostate cancer .

Cat. No.	Product Name	Target	Research Area

HY-P4082

ErbB-2-binding peptide HER2-binding peptide	EGFR	Cancer
ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. ErbB-2-binding peptide has the potential for cancer research .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a *HER2* targeting peptide that binds to *HER2* to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-P10569

*Biotin HER-2* substrate peptide**	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

HY-106204

Nelipepimut-S	EGFR	Cancer
Nelipepimut-S is a peptide vaccine which targets *HER2. Nelipepimut-S has immune activity against HER2* positive breast cancer .

HY-P10793

Cyclic(YCDGFYACYMDV)	EGFR Apoptosis	Cancer
Cyclic(YCDGFYACYMDV) is a *HER2* signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to *HER2* on cancer cells. This transformation disrupts *HER2* dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on *HER2* positive breast cancer have been demonstrated to be effective in a murine xenograft model .

HY-P10686

CH401 peptide	EGFR	Cancer
CH401 peptide is a *HER2*-derived antigen peptide. After being bound to the artificial viral capsid by a self-assembled β-cyclic peptide, CH401 peptide is encapsulated in a lipid bilayer containing the lipid adjuvant α-GalCer, and can be studied as a self-adjuvant anti-breast cancer vaccine candidate .

HY-P10648

Herceptide HER2-targeting peptide	EGFR	Cancer
Herceptide (HER2-targeting peptide) is a *HER2*-targeting peptide, and can be further conjugated to the near-infrared fluorescent dye indocyanine green (HY-D0711) (ICG) for developing theranostic agents .

HY-P5744

SPPHPSPAFSPAFDNLYYWDQ	Peptides	Inflammation/Immunology
SPPHPSPAFSPAFDNLYYWDQ is a multi-epitope class II rat HER2/neu peptide. SPPHPSPAFSPAFDNLYYWDQ can be used for the research class II HER2-DC1 vaccine studies .

HY-P5743

IRGRILHDGAYSLTLQGLGIH	Peptides	Inflammation/Immunology
IRGRILHDGAYSLTLQGLGIH is a multi-epitope class II rat HER2/neu peptide. IRGRILHDGAYSLTLQGLGIH can be used for the research class II HER2-DC1 vaccine studies .

HY-P5743A

IRGRILHDGAYSLTLQGLGIH TFA	Peptides	Inflammation/Immunology
IRGRILHDGAYSLTLQGLGIH TFA is a multi-epitope class II rat HER2/neu peptide. IRGRILHDGAYSLTLQGLGIH TFA can be used for the research class II HER2-DC1 vaccine studies .

HY-P5742

ELAAWCRWGFLLALLPPGIAG	EGFR	Cancer
ELAAWCRWGFLLALLPPGIAG (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P5742A

ELAAWCRWGFLLALLPPGIAG TFA	EGFR	Cancer
ELAAWCRWGFLLALLPPGIAG TFA (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG TFA can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P5745

TYVPANASL	Transmembrane Glycoprotein	Cancer
TYVPANASL is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL can be used to prepare J-LEAPS vaccine .

HY-P5745A

TYVPANASL TFA	MHC EGFR	Cancer
TYVPANASL TFA is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL TFA can be used to prepare J-LEAPS vaccine .

HY-P11760

HER2-targeted peptide H10	EGFR	Cancer
HER2-targeted peptide H10 is a *HER2*-targeting peptide with a K_d value of 30.4 nM. HER2-targeted peptide H10 specifically accumulates in *HER2*-positive tumor tissues of xenograft mice, when conjugated with nanoparticles. HER2-targeted peptide H10 can be used for studies related to *HER2*-positive breast cancer .

HY-P11590

WGYRGFYC	EGFR	Cancer
WGYRGFYC (WC8) is a selective *HER2*-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a K_D of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .

HY-P5744A

SPPHPSPAFSPAFDNLYYWDQ TFA	Peptides	Inflammation/Immunology
SPPHPSPAFSPAFDNLYYWDQ TFA is a multi-epitope class II rat HER2/neu peptide. SPPHPSPAFSPAFDNLYYWDQ TFA can be used for the research class II HER2-DC1 vaccine studies .

HY-P10792A

HYNIC-H6F	EGFR	Cancer
HYNIC-H6F is a SPECT imaging probe with binding specificity for human epidermal growth factor receptor 2 (HER2) domain II (IC₅₀ = 11 nM). HYNIC-H6F accumulates in *HER2*-positive breast cancer xenografts via receptor-mediated uptake, while shows low uptake in *HER2*-negative breast cancer xenografts. HYNIC-H6F enables non-invasive detection of *HER2*-positive breast cancer in mouse models and allows evaluation of *HER2* expression levels without blocking interference. HYNIC-H6F can be used in breast cancer-related research .

HY-P11613

DOTA-WC8	EGFR	Cancer
DOTA-WC8 is a *HER2*-targeting peptide probe with a K_D of 61.20 nM. ⁶⁸Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research .

HY-P11761

HYNIC-H10F	EGFR	Cancer
HYNIC-H10F is a conjugate of HER2-targeting peptide H10F and bifunctional chelator HYNIC. HYNIC-H10F can be used in breast cancer-related research .

HY-W540123

Fmoc-PNA-A(Bhoc)-OH	Biochemical Assay Reagents	Cancer
Fmoc-PNA-A(Bhoc)-OH is a protected peptide nucleic acid (PNA) monomer carrying an adenine base. Fmoc-PNA-A(Bhoc)-OH contains Fmoc and benzhydryloxycarbonyl (Bhoc) protecting groups, and serves as a standard building block designed specifically for solid-phase PNA synthesis. Fmoc-PNA-A(Bhoc)-OH can be efficiently used to synthesize PNA-based sequence-specific hybridization probes. These probes have broad applications in molecular biology research; for example, they can be used in HER2-expressing tumor-related studies, providing tools for disease diagnosis and mechanism exploration ^[2] .

HY-P11757

Cyclo[K(N3)larllt]	EGFR	Cancer
Cyclo[K(N3)larllt] is a seven-membered cyclic peptide targeting EGFR, with a K_d value of 5.09 μM, and exhibits binding selectivity toward homologous proteins *HER2* and *HER3*. Cyclo[K(N3)larllt] has no cytotoxicity and shows no growth inhibitory effect on cancer cells overexpressing EGFR. Cyclo[K(N3)larllt] can serve as a ligand for EGFR-targeted fluorescent conjugates, which is applicable to the detection of cancers with EGFR overexpression. Cyclo[K(N3)larllt] can be used in the research of colorectal cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9907

Trastuzumab Maximum Cited Publications 55 Publications Verification Anti-Human HER2, Humanized Antibody	Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody	Cancer
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to *HER2* with high affinity. Trastuzumab can be used for the research of *HER2*-positive metastatic breast cancer and gastric cancer ^[2] . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

HY-P9907A

*Trastuzumab (anti-HER2)* Maximum Cited Publications 55 Publications Verification Anti-Human HER2, Humanized Antibody (anti-HER2)	ADC Antibody EGFR	Cancer
Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9912

Pertuzumab 5+ Cited Publications	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P99380

Zanidatamab 1 Publications Verification ZW 25; ZW-49 Antibody	EGFR	Cancer
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct *HER2* epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .

HY-P99507

Zenocutuzumab MCLA-128; PB4188; R040517	EGFR	Cancer
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of *HER2* and *HER3* .

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, *HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis* and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99854

Disitamab 1 Publications Verification RC48-0	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) is a humanized monoclonal antibody targeting *HER2*. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .

HY-P991097

Pumitamig PM-8002; BNT-327	VEGFR PD-1/PD-L1	Cancer
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .

HY-P99896

Runimotamab BTRC-4017A; RG-6194	EGFR CD3	Cancer
Runimotamab (BTRC-4017A) is a *HER2* and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) ^[2].

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

HY-P9912A

*Pertuzumab (anti-HER2)*	EGFR	Cancer
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P991149

Nesfrotamig YH32367; ABL105	TNF Receptor	Cancer
Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting *HER2* and 4-1BB. The K_d values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors ^[2] .

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Cancer
Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a K_a of 3.55e-10 M for human *Her2* and a K_a of 1.17e-9 M for human PD-1. Fidasimtamab cross-links *Her2*-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on *Her2*-positive gastric cancer .

HY-P99437

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human *HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2* signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer ^[2] .

HY-P9974

Vantictumab 1 Publications Verification OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to *FZD1/2/5/7/8* receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma ^[2] .

HY-P99605

Cinrebafusp alfa PRS 343	EGFR TNF Receptor	Cancer
Cinrebafusp alfa (PRS 343) is a high affinity *CD137/HER2* bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (K_d=0.3 nM) and human monomeric CD137 (4-1BB; K_d=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research ^[2].

HY-P99030

Margetuximab MGAH-22	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-P99304

Lumretuzumab Anti-Human ERBB3 Recombinant Antibody	EGFR PI3K Akt p38 MAPK	Cancer
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer ^[2].

HY-P991588

HLX-22 AC101	EGFR Apoptosis	Cancer
HLX-22 is a humanized monoclonal antibody targeting *HER2. HLX-22 induces apoptosis* in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors ^[2].

HY-P991238

MEDI4276 Antibody	ADC Antibody EGFR	Cancer
MEDI4276 Antibody is an *HER2*-targeted antibody, which can be used for the synthesis of the ADC molecule MEDI4276. MEDI4276 Antibody can be used in the study of cancer .

HY-P990238

*Anti-Human/Rat HER2* (neu) Antibody (7.16.4)**	EGFR	Inflammation/Immunology Cancer
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is an anti-human and anti-rat *HER2* IgG2a monoclonal antibody. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) reduces tumor cell proliferation by inhibiting the HER2 signaling pathway. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can activate CD8 ⁺ T cells. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can be used for research on cancer such as breast cancer ^[2].

HY-P99630

Gancotamab antibody MM-302 antibody	EGFR	Cancer
Gancotamab antibody (MM-302) is a *HER2*-targeted antibody with antitumor activity .

HY-P99969

Inetetamab CMAB-302; Cipterbin	EGFR	Cancer
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities ^[2].

HY-P99854A

Disitamab (powder) 1 Publications Verification RC48-0 (powder)	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting *HER2*. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .

HY-P9994

Pertuzumab zuvotolimod SBT6050	Antibody-Drug Conjugates (ADCs) EGFR Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .

HY-P991779

*Anti-Mouse/Human/Canine HER2* (domain III) Antibody (H2Mab-19)**	EGFR	Cancer
Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) reacts with domain III of human and canine HER2. Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) exerts antitumor activity in mouse oral cancer xenografts. Recommend Isotype Controls: Mouse IgG2b kappa, Isotype Control (HY-P99982) .

HY-P991234

COVA208	EGFR p38 MAPK PI3K Akt	Cancer
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets *HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive* breast cancer, gastric cancer, and colorectal cancer .

HY-P991582

BI-1607	Fc Receptor (FcR)	Cancer
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .

HY-P991239

NM-02	EGFR	Cancer
NM-02 is an antibody targeting *HER2* with an EC₅₀ value of 1.2 nM. NM-02 binds to domains I and II of HER2-ECD, blocking HER2-related signaling pathways. NM-02 is promising for research of HER2-positive breast cancer .

HY-P991233

BAT1006	EGFR	Cancer
BAT1006 is a monoclonal antibody targeting *HER2* extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .

HY-P991780

*Anti-Mouse HER2* (domain I) Antibody (H2Mab-304)**	EGFR	Cancer
Anti-Mouse HER2 (domain I) Antibody (H2Mab-304) reacts with domain I of mouse HER2. HER2 is a 185 kDa transmembrane receptor tyrosine kinase that is part of the EGFR family. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979).

HY-P991236

MHES0488A DHES0815A antibody; RG-6148 antibody	EGFR DNA Alkylator/Crosslinker	Cancer
MHES0488A is a selective humanized antibody that targets *HER2* with a K_D value of 0.8 nM. MHES0488A is an antibody part of DHES0815A. MHES0488A is internalized by cells and transported to lysosomes, and then releases PBD-monoamide that enters the nucleus, alkylates DNA and induces DNA damage and apoptosis. MHES0488A is promising for research of cancers, such as HER2-positive breast cancer and gastric cancer .

HY-P991235

FS102 BMS-986186	EGFR Caspase	Cancer
FS102 is a selective Fc fragment with antigen binding (Fcab) that targets *HER2* with a K_D value of 0.8 nM. FS102 induces the degradation of HER2, activates Caspase 3/7 and disrupts the integrity of the cell membrane, triggering apoptosis of tumor cells. FS102 is promising for research of cancers such as breast cancer, gastric cancer, and colorectal cancer ^[2].

HY-P990596

Hersintuzumab	Inhibitory Antibodies	Inflammation/Immunology
Hersintuzumab is a CHO-expressed humanized antibody targeting *ERBB2/HER2/CD340*. Hersintuzumab is equipped with a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Hersintuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991977

BSI-001 5G9	EGFR Apoptosis PARP Akt ERK	Cancer
BSI-001 (5G9) is a *HER2*-targeting antibody. BSI-001 inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, *HER3, AKT* and ERK) when combined with Trastuzumab (HY-P9907) in HER2-positive cancer cells. BSI-001 exhibits synergistic anti-tumor efficacy in animal models of gastric cancer and breast cancer when combined with Trastuzumab. BSI-001 can be used for the research of *HER2*-positive breast cancer and *HER2*-overexpressing gastric cancer .

HY-P991982

ZV0201 Antibody	ADC Antibody	Cancer
ZV0201 Antibody (ZV02) is a monoclonal antibody inhibitor targeting *Her2. ZV0201 Antibody can be used to synthesize the antibody-drug conjugate (ADC) ZV0201. ZV0201 Antibody can be used to research related to HER2-positive* tumors .

HY-P992401

M802	EGFR CD3 PI3K Akt p38 MAPK Caspase Apoptosis IFNAR TNF Receptor Interleukin Related	Cancer
M802 is an anti-HER2/CD3 bispecific antibody, with a K_d of 0.578 nM for human *HER2* and a K_d of 71.2 nM for human CD3. M802 inhibits the PI3K/AKT and MAPK signaling pathways, suppresses tumor cell proliferation, activates caspase-3, and promotes tumor cell apoptosis (apoptosis). M802 recruits and activates CD3-positive immune cells, mediates cytotoxicity against *HER2*-positive tumor cells, and induces immune cells to secrete IFN-γ, TNF-α, *IL-2* and IL-6. M802 exhibits anti-tumor efficacy in mice with gastric cancer xenografts. M802 can be used in research related to *HER2*-positive breast cancer, *HER2*-positive gastric cancer and other cancers. The recommended isotype control is human IgG1 kappa (HY-P99001) .

HY-P992130

Rolditamig TQB2102 Antibody	ADC Antibody EGFR	Cancer
Rolditamig (TQB2102 Antibody) is a recombinant humanized anti-human epidermal growth factor receptor 2 (HER2) antibody. Rolditamig can be conjugated with an enzyme-cleavable linker and a topoisomerase I inhibitor to form the ADC TQB2102. Rolditamig is applicable to research on solid tumors such as HER2-positive breast cancer .

HY-P991980

H2Mab-139 H2Mab-141, H2Mab-19	EGFR	Cancer
H2Mab-139 (H2Mab-141;H2Mab-19) is an anti-HER2 monoclonal antibody. H2Mab-139 specifically binds to HER2 on various cancer cells. H₂Mab-139 can detect HER2 overexpression in colorectal cancer via flow cytometry and immunohistochemical analysis. H₂Mab-139 exhibits anti-tumor activity in mouse oral cancer and breast cancer xenografts. H2Mab-139 is applicable to research related to multiple cancers including colon cancer, oral cancer, and breast cancer ^[2].

HY-P992441

PHST001	Transmembrane Glycoprotein	Cancer
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer ^[2] .

Species:	Human (23) Rhesus Macaque (3) Mouse (5) Rat (4) Cynomolgus (5) Canine (1)
Tag:	His (26) Strep (1) Tag Free (2) Avi (10) GST (2) Fc (12)
Source:	HEK293 (38) Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P78559

	HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) ERBB2; CD340; HER-2; neu; HER2; MLN19; NEU; NGL; TKR1	Cynomolgus	HEK293
	Erb-b2 receptor tyrosine kinase 2 is a member of EGFR family. Erb-b2 receptor tyrosine kinase 2 is over-expressed in the tumors of many types of cancers. Erb-b2 receptor tyrosine kinase 2 enables ATP binding and transmembrane receptor protein tyrosine kinase activity. HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is 630 a.a., with molecular weight of 90-105 kDa.

HY-P78882

	HER2/CD340 Protein, Human (Biotinylated, HEK293, His) ERBB2; CD340; HER-2; neu; HER2; MLN19; NEU; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Her2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P701268

	*FITC-Labeled HER2/CD340 Protein, Human (HEK293, Fc)* ERBB2; CD340; HER-2; neu; HER2; MLN19; NEU; NGL; TKR1	Human	HEK293
	FITC-Labeled HER2/CD340 Protein, Human (HEK293, Fc) is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. FITC-Labeled HER2/CD340 Protein, Human (HEK293, Fc), expressed by HEK293 , with Fc labeled tag.

HY-P700887

	HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; NGL; TKR1; ERBB2; NEU; ENV; ENVW; ERVWE1; HERV7Q; HERVW	Cynomolgus	HEK293
	Erb-b2 receptor tyrosine kinase 2 is a member of EGFR family. Erb-b2 receptor tyrosine kinase 2 is over-expressed in the tumors of many types of cancers. Erb-b2 receptor tyrosine kinase 2 enables ATP binding and transmembrane receptor protein tyrosine kinase activity. HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P705027

	HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, Fc-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; NGL; TKR1; ERBB2; NEU; ENV; ENVW; ERVWE1; HERV7Q; HERVW	Cynomolgus	HEK293

HY-P78451

	HER2/CD340 Protein, Human (HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P78138

	HER2/CD340 Protein, Human (Biotinylated, HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P78679

	HER2/CD340 Protein, Human (S310F, HEK293, His) ERBB2; CD340; HER-2/neu; HER2; MLN19; NEU; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (S310F, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag and S310F, , , , mutation.

HY-P78680

	HER2/CD340 Protein, Human (S310Y, HEK293, His) ERBB2; CD340; HER-2/neu; HER2; MLN19; NEU; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (S310Y, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-10*His labeled tag and S310Y mutation.

HY-P74895

	HER2/CD340 Protein, Rat (HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Rat	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics.Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability.HER2/CD340 Protein, Rat (HEK293, His) is the recombinant rat-derived HER2/CD340 protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P74897

	HER2/CD340 Protein, Canine (HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Canine	HEK293
	The HER2/CD340 Protein is a member of the receptor tyrosine kinase family. HER2/CD340 Protein participates in the PI3K/Akt signaling pathway to regulate the differentiation and apoptosis of neural stem cells in the cochlear nucleus. HER2/CD340 Protein is an overexpressed oncogenic factor in bladder cancer that activates the oncogenic signaling pathway, thereby promoting tumor cell survival/proliferation. HER2/CD340 Protein, Canine (HEK293, His) is the recombinant canine-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P74896

	HER2/CD340 Protein, Rat (HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Rat	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics.Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability.HER2/CD340 Protein, Rat (HEK293, Fc) is the recombinant rat-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P77533

	HER2/CD340 Protein, Human (Biotinylated, HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, HEK293, Fc) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73097

	HER2/CD340 Protein, Rat (HEK293) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Rat	HEK293
	The HER2/CD340 Protein is a member of the receptor tyrosine kinase family.HER2/CD340 Protein participates in the PI3K/Akt signaling pathway to regulate the differentiation and apoptosis of neural stem cells in the cochlear nucleus.HER2/CD340 Protein is an overexpressed oncogenic factor in bladder cancer that activates the oncogenic signaling pathway, thereby promoting tumor cell survival/proliferation.HER2/CD340 Protein, Rat (HEK293) is the recombinant rat-derived HER2/CD340 protein, expressed by HEK293 , with tag free.

HY-P73094

	HER2/CD340 Protein, Human (HEK293) 1 Publications Verification Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with tag free.

HY-P73929

	HER2/CD340 Protein, Mouse (HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Mouse	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Mouse (HEK293, His) is the recombinant mouse-derived HER2/CD340 protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P78652

	*FITC-Labeled HER2/CD340 Protein, Human (HEK293, His)* Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. FITC-Labeled HER2/CD340 Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P73930

	HER2/CD340 Protein, Mouse (HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Mouse	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73929A

	HER2/CD340 Protein, Mouse (HEK293, N-His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Mouse	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Mouse (HEK293, N-His) is the recombinant mouse-derived HER2/CD340 protein, expressed by HEK293 , with N-His labeled tag.

HY-P705254

	HER2/CD340 Protein, Mouse (Biotinylated, HEK293, Fc-Avi) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Mouse	HEK293

HY-P705255

	HER2/CD340 Protein, Mouse (Biotinylated, HEK293, His-Avi) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Mouse	HEK293

HY-P77535

	HER2/CD340 Protein, Human (Biotinylated, Domain 4, HEK293, His-Avi) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, Domain 4, HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-His-Avi labeled tag.

HY-P73095

	HER2/CD340 Protein, Human (Domain 4, HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (142a.a, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P73931

	HER2/CD340 Protein, Human (Biotinylated, 173a.a, HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, 173a.a, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P706042

	HER2/CD340 Protein, Human (Active, sf9, His-GST) Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; HER2; MLN19; NEU; NGL	Human	Sf9 insect cells

HY-P706043

	HER2/CD340 Protein, Human (Active, L755S, sf9, His-GST) Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; HER2; MLN19; NEU; NGL	Human	Sf9 insect cells

HY-P705313

	*HLA-A02:01&B2M&HER2(KIFGSLAFL) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A0201 & B2M & HER*2 (KIFGSLAFL)	Human	HEK293

HY-P705314

	*HLA-A02:01&B2M&HER2(LIAHNQVRQV) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A0201 & B2M & HER*2 (LIAHNQVRQV)	Human	HEK293

HY-P70254

	HER2/CD340 Protein, Human (HEK293, His) rHuReceptor tyrosine-protein kinase erbB-2/HER2, His; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; ERBB2; MLN19; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P704335

	HER2/CD340 Protein, Human (HEK293, mFc) rHuReceptor tyrosine-protein kinase erbB-2/HER2, His; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; ERBB2; MLN19; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, mFc) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293, with C-mFc labeled tag.

HY-P704660

	HER2/CD340 Protein, Human (HEK293, Twin Strep) rHuReceptor tyrosine-protein kinase erbB-2/HER2, His; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; ERBB2; MLN19; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, Twin Strep) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293, with C-Twin-Strep labeled tag.

HY-P70759

	HER2/CD340 Protein, Human (HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; ERBB2; MLN19; NGL; TKR1	Human	HEK293
	HER2/CD340 Protein, Human (HEK293, Fc) is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, Fc) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P704658

	HER2/CD340 Protein, Human (151a.a, HEK293, His) rHuReceptor tyrosine-protein kinase erbB-2/HER2, His; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; ERBB2; MLN19; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (151a.a, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293, with C-His labeled tag.

HY-P704659

	HER2/CD340 Protein, Human (488a.a, HEK293, His) rHuReceptor tyrosine-protein kinase erbB-2/HER2, His; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; ERBB2; MLN19; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (488a.a, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293, with C-His labeled tag.

HY-P72626

	HER2/CD340 Protein, Rat (His) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Rat	E. coli
	The HER2/CD340 protein is a key protein tyrosine kinase that is a component of multiple cell surface receptor complexes and requires coreceptors for ligand binding.Its interaction within the neuregulin-receptor complex depends on neuregulin, and GP30 emerges as a potential ligand.HER2/CD340 Protein, Rat (His) is the recombinant rat-derived HER2/CD340 protein, expressed by E.coli , with C-6*His labeled tag.

HY-P75805

	HER2/CD340 Protein, Cynomolgus (HEK293, His) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Cynomolgus	HEK293
	Erb-b2 receptor tyrosine kinase 2 is a member of EGFR family. Erb-b2 receptor tyrosine kinase 2 is over-expressed in the tumors of many types of cancers. Erb-b2 receptor tyrosine kinase 2 enables ATP binding and transmembrane receptor protein tyrosine kinase activity. HER2/CD340 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P75807

	HER2/CD340 Protein, Rhesus Macaque (HEK293, His) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Rhesus Macaque	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P75806

	HER2/CD340 Protein, Rhesus Macaque (HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Rhesus Macaque	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P75804

	HER2/CD340 Protein, Rhesus Macaque (D121N, L122P, HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Rhesus Macaque	HEK293
	Erb-b2 receptor tyrosine kinase 2 is a member of EGFR family. Erb-b2 receptor tyrosine kinase 2 is over-expressed in the tumors of many types of cancers. Erb-b2 receptor tyrosine kinase 2 enables ATP binding and transmembrane receptor protein tyrosine kinase activity. HER2/CD340 Protein, Rhesus Macaque (D121N, L122P, HEK293, Fc) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P704657

	HER2/CD340 Protein, Cynomolgus (HEK293, hFc) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Cynomolgus	HEK293
	HER2/CD340 Protein, Cynomolgus (HEK293, hFc) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293, with C-hFc tag.

HY-P72374

	HER2/CD340 Protein, Human (Biotinylated, HEK293, Fc-Avi) Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor ERBB2; MLN19; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (7) Rabbit (6)
Reactivity:	Human (13) Rat (4) Mouse (6)
Application:	IHC-P (9) ICC/IF (7) mIHC (1) IF-Tissue (2) IP (4) IHC-F (4) WB (13) FC (4) ELISA (5)
Isotype:	IgG (8) IgG1 (5)
Conjugation:	Non-conjugated (13) Biotin (13)
Clonality:	Polyclonal (1) Monoclonal (6) Recombinant (1)
Modification:	Phosphorylated (2) Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83946

	*C-erbB-2/HER2* Antibody (YA3643)** NEU; HER2; TKR1; CD340; HER-2	WB, IHC-P, FC, ELISA	Human, Mouse
	C-erbB-2/HER2 Antibody (YA3643) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C-erbB-2/HER2.

HY-P83946A

	*C-erbB-2/HER2* Antibody (YA3643)(PBS only)** NEU; HER2; TKR1; CD340; HER-2	WB, IHC-P, FC, ELISA	Human
	C-erbB-2/HER2 Antibody (YA3643) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C-erbB-2/HER2.

HY-P83761

	*Phospho-C-erbB-2/HER2(Tyr1221/Tyr1222) Antibody* ERBB2; HER2; MLN19; NEU; NGL; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340	WB, IHC-P, IP, ELISA	Human, Mouse
	Phospho-C-erbB-2/HER2(Tyr1221/Tyr1222) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-C-erbB-2/HER2(Tyr1221/Tyr1222).

HY-P80658

	*C-erbB-2/HER2* Antibody (YA771)** ERBB2; HER2; MLN19; NEU; NGL; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340	WB, IHC-F, IHC-P, ICC/IF	Human, Mouse, Rat
	C-erbB-2/HER2 Antibody (YA771) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C-erbB-2/HER2.

HY-P810657

	*Phospho-HER2* / ErbB2 (Tyr1248) Antibody (YA9917)** ERBB2; HER2; MLN19; NEU; NGL; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340	WB, ICC/IF	Human
	Phospho-HER2 / ErbB2 (Tyr1248) Antibody (YA9917) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-HER2 / ErbB2 (Tyr1248).

HY-P80658A

	*C-erbB-2/HER2* Antibody (YA771)(PBS only)** ERBB2; HER2; MLN19; NEU; NGL; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340	WB, IHC-F, IHC-P, ICC/IF	Human, Mouse, Rat
	C-erbB-2/HER2 Antibody (YA771) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C-erbB-2/HER2.

HY-P810658

	*Phospho-HER2* / ErbB2 (Thr686) Antibody (YA9918)** ERBB2; HER2; MLN19; NEU; NGL; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340	WB, IP	Human, Mouse, Rat
	Phospho-HER2 / ErbB2 (Thr686) Antibody (YA9918) is a Mouse-derived and non-conjugated IgG1 Monoclonal antibody, targeting to Phospho-HER2 / ErbB2 (Thr686).

HY-P810659

	*Phospho-HER2* / ErbB2 (Tyr1139) Antibody (YA9919)** ERBB2; HER2; MLN19; NEU; NGL; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340	WB, ICC/IF, FC	Human
	Phospho-HER2 / ErbB2 (Tyr1139) Antibody (YA9919) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-HER2 / ErbB2 (Tyr1139).

HY-P86719

	*C-erbB-2/HER2* Antibody (YA6411)** Erb-B2 Receptor Tyrosine Kinase 2; NGL; NEU; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; Tyrosine Kinase-Type Cell Surface Receptor HER2; Neuro/Glioblastoma Derived Oncogene Homolog; Human Epidermal Growth Factor Receptor 2; Metastatic Lymph Node Gene 19 Protein; Proto-Oncogene C-ErbB-2; Proto-Oncogene Neu; EC 2.7.10.1; P185erbB2; MLN 19; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2; Neuroblastoma/Glioblastoma Derived Oncogene Homolog; Receptor Tyrosine-Protein Kinase ErbB-2; C-Erb B2/Neu Protein; CD340 Antigen; HERstatin; EC 2.7.10; CD340; HER-2; MLN19; TKR1;	WB, IHC-P, IHC-F, IF-Tissue	Human
	C-erbB-2/HER2 Antibody (YA6411) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-2/HER2.

HY-P86719A

	*C-erbB-2/HER2* Antibody (YA6411)(PBS only)** Erb-B2 Receptor Tyrosine Kinase 2; NGL; NEU; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; Tyrosine Kinase-Type Cell Surface Receptor HER2; Neuro/Glioblastoma Derived Oncogene Homolog; Human Epidermal Growth Factor Receptor 2; Metastatic Lymph Node Gene 19 Protein; Proto-Oncogene C-ErbB-2; Proto-Oncogene Neu; EC 2.7.10.1; P185erbB2; MLN 19; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2; Neuroblastoma/Glioblastoma Derived Oncogene Homolog; Receptor Tyrosine-Protein Kinase ErbB-2; C-Erb B2/Neu Protein; CD340 Antigen; HERstatin; EC 2.7.10; CD340; HER-2; MLN19; TKR1;	WB, IHC-P, IHC-F, IF-Tissue	Human
	C-erbB-2/HER2 Antibody (YA6411) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-2/HER2.

HY-P86242

	*C-erbB-2/HER2* Antibody (YA5934)** Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	C-erbB-2/HER2 Antibody (YA5934) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-2/HER2.

HY-P86166

	*Phospho-C-erbB-2/HER2(Tyr1221/Tyr1222) Antibody (YA5858)* Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340;	WB, ICC/IF, IP, ELISA	Human
	Phospho-C-erbB-2/HER2(Tyr1221/Tyr1222) Antibody (YA5858) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-C-erbB-2/HER2(Tyr1221/Tyr1222).

HY-P80500

	*C-erbB-2/HER2* Antibody (YA388)**	WB, IHC-P, ICC/IF, FC, mIHC	Human
	C-erbB-2/HER2 Antibody (YA388) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-2/HER2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-10223

CUDC-101 5+ Cited Publications		Alkynes
CUDC-101 is a potent inhibitor of HDAC, EGFR, and *HER2* with IC₅₀s of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-133736

PROTAC BRD4 Degrader-5-CO-PEG3-N3		Azide PROTAC Synthesis
PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader (MZ 1 (HY-107425) analog) and PEG-based linker. PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. PROTAC BRD4 Degrader-5-CO-PEG3-N3 can be used for the research of *HER2*-positive breast cancer .

HY-163099

P5(PEG24)-VC-PAB-Exatecan		Alkynes
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .

HY-159519

*EGFR/HER2-IN-16*		Azide
EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of EGFR (IC₅₀=6.15 nM) and *HER-2* (IC₅₀=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research .

HY-154802

TCO-GK-PEG4-NHS ester		TCO ADC Synthesis
TCO-GK-PEG4-NHS ester is an ADC Linker, and can be used for synthesis of ^[18F]AlF-NOTA-Tz-TCO-GK-2Rs15d. ^[18F]AlF-NOTA-Tz-TCO-GK-2Rs15d binds with high affinity and immunoreactivity to *HER2* . TCO-GK-PEG4-NHS ester is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

HY-P11757

Cyclo[K(N3)larllt]		Azide
Cyclo[K(N3)larllt] is a seven-membered cyclic peptide targeting EGFR, with a K_d value of 5.09 μM, and exhibits binding selectivity toward homologous proteins *HER2* and *HER3*. Cyclo[K(N3)larllt] has no cytotoxicity and shows no growth inhibitory effect on cancer cells overexpressing EGFR. Cyclo[K(N3)larllt] can serve as a ligand for EGFR-targeted fluorescent conjugates, which is applicable to the detection of cancers with EGFR overexpression. Cyclo[K(N3)larllt] can be used in the research of colorectal cancer .

Cat. No.	Product Name		Classification

HY-RS04466

ERBB2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
ERBB2 Human Pre-designed siRNA Set A contains three designed siRNAs for ERBB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-158828

SSO111 sodium		Antisense Oligonucleotides
SSO111 sodium, a 20mer fully modified antisense oligonucleotide, targets the oncogene?HER2. SSO111 sodium induces exon 15 skipping during splicing, leading to the generation of a novel mRNA transcript that excludes exon 15. SSO111 sodium downregulated *HER2* mRNA, which resulted in the inhibition of proliferation and induction of apoptosis in HER2-overexpressing tumor cells.

HY-RS04467

Erbb2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Erbb2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Erbb2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HER-2

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products